MedTrace Logo

Evaluating Clinical Hiatal Hernia Outcomes Using OviTex®

NCT07070115 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 173

Last updated 2026-02-09

No results posted yet for this study

Summary

This study will evaluate hiatal hernia recurrence rate and post-operative complications following the use of OviTex Core Resorbable or OviTex 1S Resorbable.

Conditions

  • Hiatal Hernia

Interventions

DEVICE

OviTex Reinforced Tissue Matrix

All study subjects will receive OviTex. All OviTex Reinforced Tissue Matrices are intended for use as a surgical mesh to reinforce or repair soft tissue where weakness exists.

Sponsors & Collaborators

  • Tela Bio Inc

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
22 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-07-25
Primary Completion
2031-12-31
Completion
2032-07-31
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07070115 on ClinicalTrials.gov